Abstract
Introduction: Castration-resistant prostate cancer (CRPC) is a lethal form of advanced prostate cancer (PCa), that remains reliant on reactivated and often highly augmented AR signaling. Improving therapeutic strategies is crucial to maximize patient survival, but requires comprehensive testing on robust and representative preclinical models. Patient-derived xenografts (PDXs) from CRPC patients on contemporary therapies are scarce and provide an incomplete representation of CRPC heterogeneity. Complementing our existing PDX panel, we now introduce a new set of five AR-positive (AR+) PDXs and matching PDX-derived organoids (PDXOs) obtained from heavily pretreated CRPC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
